Outpatient Infusion

Aduhelm


Thrivewell now offers Aduhelm infusion therapy for the treatment of Alzheimer’s for patients at all of our Queens, Brooklyn, Long Island, and Westchester New York locations!

Aduhelm represents a first-of-its-kind treatment approved for Alzheimer’s disease. It is the first new treatment approved for Alzheimer’s since 2003 and is the first therapy that targets the fundamental pathophysiology of the disease.

Aducanumab, sold under the brand name Aduhelm, is indicated for the treatment of Alzheimer’s disease (AD). It is an amyloid beta-directed monoclonal antibody.

Aducanumab targets aggregated forms of β-amyloid found in the brains of people with Alzheimer’s disease, in the hopes of reducing its buildup.

Aducanumab was approved for medical use in the United States in June 2021, and it represents a first-of-its-kind treatment approved for Alzheimer’s disease. It is the first new treatment approved for Alzheimer’s since 2003, and is the first therapy that targets the fundamental pathophysiology of the disease. Aducanumab’s approval was controversial due to ambiguous clinical trial results surrounding its efficacy. The drug was approved under the FDA’s accelerated approval pathway, and the FDA required a follow-up study to see if the drug helps treat symptoms of Alzheimer’s.

Copyright by Thrivewell 2017. All rights reserved.